Short answer
UroGen Pharma Ltd. (URGN) filed an 8-K current report with the SEC on June 23, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Shareholders approved director and officer insurance changes within the compensation policy.
UroGen Pharma Ltd. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Shareholders approved director and officer insurance changes within the compensation policy
- 2017 Equity Incentive Plan expanded by 1,000,000 ordinary shares
- Larger equity pool supports employee and director retention but creates potential shareholder dilution
- Amendments previously board-approved March 19, 2026 and now effective following shareholder approval
Item 5.07 · Submission of Matters to a Vote of Security Holders
- All seven director nominees elected, preserving board continuity through the next annual meeting
- Amended and restated Articles of Association approved, changing the company’s governing framework
- Compensation Policy Amendment and 2017 Amended Equity Incentive Plan approved, supporting executive pay flexibility and equity awards
- Executive compensation approved on an advisory basis with 25,125,846 votes for
- PricewaterhouseCoopers LLP approved as independent auditor through the 2027 annual meeting with 36,778,509 votes for
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other UroGen Pharma Ltd. 8-K filings
Get the next URGN 8-K as it lands
Follow URGN for push alerts, or ask the research agent what this filing means.